EXEL
Price
$36.99
Change
+$0.01 (+0.03%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
10.19B
Earnings call today
VRTX
Price
$431.81
Change
-$7.56 (-1.72%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
112.83B
79 days until earnings call
Ad is loading...

EXEL vs VRTX

Header iconEXEL vs VRTX Comparison
Open Charts EXEL vs VRTXBanner chart's image
Exelixis
Price$36.99
Change+$0.01 (+0.03%)
Volume$73.62K
Capitalization10.19B
Vertex Pharmaceuticals
Price$431.81
Change-$7.56 (-1.72%)
Volume$23.8K
Capitalization112.83B
EXEL vs VRTX Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. VRTX commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and VRTX is a Buy.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (EXEL: $36.98 vs. VRTX: $439.37)
Brand notoriety: EXEL: Notable vs. VRTX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 102% vs. VRTX: 116%
Market capitalization -- EXEL: $10.19B vs. VRTX: $112.83B
EXEL [@Biotechnology] is valued at $10.19B. VRTX’s [@Biotechnology] market capitalization is $112.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 2 green FA rating(s).

  • EXEL’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 2 green, 3 red.
According to our system of comparison, EXEL is a better buy in the long-term than VRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).

  • EXEL’s TA Score: 4 bullish, 6 bearish.
  • VRTX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а -7.18% price change this week, while VRTX (@Biotechnology) price change was -12.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.49%. For the same industry, the average monthly price growth was +10.87%, and the average quarterly price growth was -7.60%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

VRTX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($113B) has a higher market cap than EXEL($10.2B). VRTX has higher P/E ratio than EXEL: VRTX (32.17) vs EXEL (21.01). EXEL YTD gains are higher at: 11.051 vs. VRTX (9.106). EXEL has higher annual earnings (EBITDA): 719M vs. VRTX (486M). VRTX has more cash in the bank: 6.12B vs. EXEL (1.11B). EXEL has less debt than VRTX: EXEL (191M) vs VRTX (1.75B). VRTX has higher revenues than EXEL: VRTX (11B) vs EXEL (2.17B).
EXELVRTXEXEL / VRTX
Capitalization10.2B113B9%
EBITDA719M486M148%
Gain YTD11.0519.106121%
P/E Ratio21.0132.1765%
Revenue2.17B11B20%
Total Cash1.11B6.12B18%
Total Debt191M1.75B11%
FUNDAMENTALS RATINGS
EXEL vs VRTX: Fundamental Ratings
EXEL
VRTX
OUTLOOK RATING
1..100
1065
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
2627
SMR RATING
1..100
4191
PRICE GROWTH RATING
1..100
4362
P/E GROWTH RATING
1..100
8931
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (74) in the Biotechnology industry is in the same range as VRTX (79). This means that EXEL’s stock grew similarly to VRTX’s over the last 12 months.

EXEL's Profit vs Risk Rating (26) in the Biotechnology industry is in the same range as VRTX (27). This means that EXEL’s stock grew similarly to VRTX’s over the last 12 months.

EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for VRTX (91). This means that EXEL’s stock grew somewhat faster than VRTX’s over the last 12 months.

EXEL's Price Growth Rating (43) in the Biotechnology industry is in the same range as VRTX (62). This means that EXEL’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's P/E Growth Rating (31) in the Biotechnology industry is somewhat better than the same rating for EXEL (89). This means that VRTX’s stock grew somewhat faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELVRTX
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
46%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
45%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
43%
Advances
ODDS (%)
Bullish Trend 9 days ago
64%
Bullish Trend 14 days ago
61%
Declines
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 5 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 2 days ago
39%
View a ticker or compare two or three
Ad is loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

EXEL and

Correlation & Price change

A.I.dvisor tells us that EXEL and VRTX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and VRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+2.24%
VRTX - EXEL
32%
Poorly correlated
+3.38%
CGON - EXEL
31%
Poorly correlated
+5.98%
RIGL - EXEL
29%
Poorly correlated
-0.85%
INCY - EXEL
29%
Poorly correlated
+3.17%
RVMD - EXEL
28%
Poorly correlated
+3.61%
More

VRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with KRYS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRTX
1D Price
Change %
VRTX100%
+3.38%
KRYS - VRTX
45%
Loosely correlated
+5.48%
CCCC - VRTX
40%
Loosely correlated
+7.48%
SNDX - VRTX
39%
Loosely correlated
+2.71%
RGNX - VRTX
39%
Loosely correlated
+5.98%
REGN - VRTX
38%
Loosely correlated
+9.07%
More